- Home
- IPSC
as 11-28-2025 12:40pm EST
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 45.4M | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $1.83 | Next Earning Date: | 11-13-2025 |
| Revenue: | $113,337,000 | Revenue Growth: | 4122.69% |
| Revenue Growth (this year): | 1589.94% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Century Therapeutics Inc. (IPSC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cowan Chad | IPSC | Chief Scientific Officer | Nov 20 '25 | Sell | $0.50 | 5,462 | $2,736.46 | 987,027 | |
| Pfeiffenberger Brent | IPSC | President and CEO | Nov 19 '25 | Buy | $0.50 | 35,000 | $17,328.50 | 3,271,453 | |
| Pfeiffenberger Brent | IPSC | President and CEO | Nov 17 '25 | Sell | $0.45 | 32,456 | $14,735.02 | 3,236,453 | |
| Carr Douglas | IPSC | SVP Finance & Operations | Nov 3 '25 | Sell | $0.59 | 292 | $171.11 | 405,131 | |
| Pfeiffenberger Brent | IPSC | President and CEO | Sep 8 '25 | Sell | $0.50 | 488 | $244.00 | 3,236,453 | |
| Russotti Gregory | IPSC | See Remarks | Sep 8 '25 | Sell | $0.50 | 539 | $269.50 | 391,508 | |
| Carr Douglas | IPSC | SVP Finance & Operations | Sep 8 '25 | Sell | $0.50 | 263 | $131.50 | 405,131 |
Latest Century Therapeutics Inc. News
IPSC Breaking Stock News: Dive into IPSC Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
MT Newswires
11 days ago
Century Therapeutics Shares Fall After Leerink Partners Downgrade
GlobeNewswire
15 days ago
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
15 days ago
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
GlobeNewswire
a month ago
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Simply Wall St.
2 months ago
We Think Century Therapeutics (NASDAQ:IPSC) Needs To Drive Business Growth Carefully
Zacks
5 months ago
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
Zacks
6 months ago
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Compare IPSC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPSC Century Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.